Longitudinal kidney function outcome in aging testicular cancer survivors

References

• Bilici A, Ozturk T, Turkmen E, et al. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology. World J Urol. 2015;33(10):1613–1622.
   PubMed Web of Science ®Google Scholar
• Khader J, Salem A, Abuodeh Y, et al. Stage I seminoma: treatment outcome at King Hussein Cancer Center in Jordan. BMC Urol. 2012;12: 10(1).
   PubMedGoogle Scholar
• Glaser SM, Vargo JA, Balasubramani GK, et al. Surveillance and radiation therapy for stage I seminoma–have we learned from the evidence? Int J Radiat Oncol Biol Phys. 2016;94(1):75–84.
   PubMed Web of Science ®Google Scholar
• Vaz RM, Bordenali G, Bibancos M. Testicular cancer-surgical treatment. Front Endocrinol. 2019;10:308.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87(3):293–298.
   PubMed Web of Science ®Google Scholar
• Znaor A, Lortet-Tieulent J, Jemal A, et al. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65(6):1095–1106.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Aass N, Fossa SD, et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv. 2008;2(3):128–137.
   PubMedGoogle Scholar
• Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 2005;23(16):3718–3725.
   PubMed Web of Science ®Google Scholar
• Hjelle LV, Bremnes RM, Gundersen PO, et al. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urol Oncol. 2016;34:487 e13-487–e20.
   PubMed Web of Science ®Google Scholar
• Curreri SA, Fung C, Beard CJ. Secondary malignant neoplasms in testicular cancer survivors. Urol Oncol. 2015;33(9):392–398.
   PubMed Web of Science ®Google Scholar
• Brydoy M, Fossa SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97:1580–1588.
   PubMed Web of Science ®Google Scholar
• Flentje M, Hensley F, Gademann G, et al. Renal tolerance to nonhomogenous irradiation: comparison of observed effects to predictions of normal tissue complication probability from different biophysical models. Int J Radiat Oncol Biol Phys. 1993;27(1):25–30.
   PubMed Web of Science ®Google Scholar
• Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol. 1990;8(1):21–26.
   PubMed Web of Science ®Google Scholar
• Lauritsen J, Mortensen MS, Kier MG, et al. Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol. 2015;26(1):173–178.
   PubMed Web of Science ®Google Scholar
• Inai H, Kawai K, Ikeda A, et al. Risk factors for chronic kidney disease after chemotherapy for testicular cancer. Int J Urol. 2013;20(7):716–722.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Aass N, Fossa SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol. 2007;18(2):241–248.
   PubMed Web of Science ®Google Scholar
• Sprauten M, Haugnes HS, Brydoy M, et al. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol. 2015;26(10):2133–2140.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Alfsen GC, Lien HH, et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21(17):3310–3317.
   PubMed Web of Science ®Google Scholar
• Aass N, Fossa SD, Ous S, et al. Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-seminomatous testicular cancer? Br J Urol. 1990;65(4):385–390.
   PubMedGoogle Scholar
• Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–1440.
   PubMed Web of Science ®Google Scholar
• Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15(5):1844–1852.
   PubMed Web of Science ®Google Scholar
• Horwich A, Oliver RT, Wilkinson PM, et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer. 2000;83(12):1623–1629.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Paluchowska B, Horwich A, et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer. 2005;93:1209–1214.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Droz JP, Stoter G, et al. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer. 1995;71:619–624.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17:1146
   PubMed Web of Science ®Google Scholar
• Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9(1):13–21.
   PubMed Web of Science ®Google Scholar
• Krokstad S, Langhammer A, Hveem K, et al. Cohort profile: the HUNT study, Norway. Int J Epidemiol. 2013;42(4):968–977.
   PubMed Web of Science ®Google Scholar
• Holmen J, Midthjell K, Krüger Ø, et al. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): objectives, contents, methods and participation. Norsk Epidemiologi. 2003;13:19–32.
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52(1):5–18.
   PubMed Web of Science ®Google Scholar
• Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49–61.
   PubMed Web of Science ®Google Scholar
• Sagstuen H, Aass N, Fossa SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol. 2005;23(22):4980–4990.
   PubMed Web of Science ®Google Scholar
• Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663.
   PubMed Web of Science ®Google Scholar
• Kost S, Dorr W, Keinert K, et al. Effect of dose and dose-distribution in damage to the kidney following abdominal radiotherapy. Int J Radiat Biol. 2002;78:695–702.
   PubMed Web of Science ®Google Scholar
• Hansen SW, Groth S, Daugaard G, et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol. 1988;6(11):1728–1731.
   PubMed Web of Science ®Google Scholar
• Moul JW, Robertson JE, George SL, et al. Complications of therapy for testicular cancer. J Urol. 1989;142(6):1491–1496.
   PubMed Web of Science ®Google Scholar
• Stoter G, Koopman A, Vendrik CP, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989;7(8):1099–1104.
   PubMed Web of Science ®Google Scholar
• Bissett D, Kunkeler L, Zwanenburg L, et al. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer. 1990;62(4):655–659.
   PubMed Web of Science ®Google Scholar
• Osanto S, Bukman A, Van Hoek F, et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992;10(4):574–579.
   PubMed Web of Science ®Google Scholar
• Suer E, Mermerkaya M, Gulpinar O, et al. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor? J Urol. 2013;190(6):2081–2085.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Aass N, Winderen M, et al. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol. 2002;13:222–228.
   PubMed Web of Science ®Google Scholar
• Cost NG, Adibi M, Lubahn JD, et al. Effect of testicular germ cell tumor therapy on renal function. Urology. 2012;80(3):641–648.
   PubMed Web of Science ®Google Scholar
• Hamilton CR, Bliss JM, Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol. 1989;25(2):185–189.
   PubMedGoogle Scholar
• MacLeod PM, Tyrell CJ, Keeling DH. The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol. 1988;39(2):190–192.
   PubMed Web of Science ®Google Scholar
• Latcha S, Jaimes EA, Patil S, et al. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11(7):1173–1179.
   PubMed Web of Science ®Google Scholar
• Fjeldborg P, Sørensen J, Helkaer PE. The long-term effect of cisplatin on renal function. Cancer. 1986;58(10):2214–2217.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol. 1988;21(2):163–167.
   PubMed Web of Science ®Google Scholar
• Garcia-Pastor C, Blazquez-Serra R, Bosch RJ, et al. Apoptosis and cell proliferation in proximal tubular cells exposed to apoptotic bodies. Novel pathophysiological implications in cisplatin-induced renal injury. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2504-2525.
   Google Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007.
   PubMed Web of Science ®Google Scholar
• Walker RJ, Wall ML, Vijay S, et al. Accelerated development of mesenteric and renal artery calcific atherosclerosis following radiotherapy for testicular cancer. J Surg Case Rep 2014. 2014;9.
   Google Scholar
• Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Cathet Cardiovasc Intervent. 2008;72(4):563–568.
   PubMed Web of Science ®Google Scholar
• Boeckman HJ, Trego KS, Turchi JJ. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res. 2005;3(5):277–285.
   PubMed Web of Science ®Google Scholar
• Trendowski MR, El-Charif O, Ratain MJ, et al. Clinical and genome-wide analysis of serum platinum levels after cisplatin-based chemotherapy. Clin Cancer Res. 2019;25(19):5913–5924.
   PubMed Web of Science ®Google Scholar
• Soon JA, Anton A, Torres J, et al. Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature. Support Care Cancer. 2019;27(2):373–382.
   PubMed Web of Science ®Google Scholar
• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4):S117–S31.
   PubMed Web of Science ®Google Scholar
• Hallan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med. 2007;167(22):2490–2496.
   PubMedGoogle Scholar
• Kvammen O, Myklebust TA, Solberg A, et al. Long-term relative survival after diagnosis of testicular germ cell tumor. Cancer Epidemiol Biomarkers Prev. 2016;25(5):773–779.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. Clin J Am Soc Nephrol. 2009;20(11):2305–2313.
   PubMed Web of Science ®Google Scholar
• Hallan SI, Ovrehus MA, Romundstad S, et al. Long-term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway. Kidney Int. 2016;90(3):665–673.
   PubMed Web of Science ®Google Scholar